Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer

Annals of Nuclear Medicine

Volumn 26, Issue 2, 2012, Pages 175-183

  Kim, Bom Sahn ^a   Sung, Sun Hee ^b  

^a Mokdong Hospital   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

Author keywords

18F FDG; Axillary lymph node; Biologic markers; Breast cancer; SUV

Indexed keywords

CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; MONOCLONAL ANTIBODY D2-40; PROGESTERONE RECEPTOR; PROTEIN P53; DIAGNOSTIC AGENT; ERBB2 PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER SIZE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TRIPLE NEGATIVE BREAST CANCER; AGED; BREAST TUMOR; EVALUATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84858698462     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0556-1     Document Type: Article

References (39)

1. Barrett SV. Breast cancer. J R Coll Physic Edinb. 2010;40(4):335-8. (quiz 9).
2. Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34(12):1915-24. (Pubitemid 350212117)
3. Groheux D, Giacchetti S, Rubello D, Al-Nahhas A, Moretti JL, Espie M, et al. The evolving role of PET/CT in breast cancer. Nucl Med Commun. 2010;31(4):271-3.
4. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112(5):995-1000. (Pubitemid 351304582)
5. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espie M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426-35.
6. Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36(10):1543-50.
7. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38(4):250-8. (Pubitemid 351583988)
8. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18(3):473-8. (Pubitemid 46359625)
9. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18(20):3495-502.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology. 1991;19:403-10.
11. (Histopathology. 2002;41(3A):151-2 (discussion 2-3)).
12. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 1995;26(8):873-9.
13. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-68. (Pubitemid 28144151)
14. Zafrani B, Aubriot MH, Mouret E, De Cremoux P, De Rycke Y, Nicolas A, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology. 2000;37(6):536-45. (Pubitemid 32099165)
15. Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol. 2004;35(6):647-53. (Pubitemid 41404651)
16. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer. 2006;94(11):1643-9. PMCID: 2361306. (Pubitemid 43924927)
17. Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42(1):9-16. (Pubitemid 32104770)
18. Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging. 2008;35(3):475-83. (Pubitemid 351661670)
19. Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15(6):588-93.
20. Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hagiike M, et al. Preoperative FDG-PET for axillary metastases in patients with breast cancer. Arch Surg. 2006;141(8):783-8. (discussion 8-9).
21. Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96(2):166-70.
22. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25(10):1429-34. (Pubitemid 28464119)
23. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14(3):260-8.
24. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDGPET in primary breast cancer. Breast Cancer Res Treat. 2006;98(3):267-74. (Pubitemid 44195596)
25. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg. 2007;73(11):1151-7. (Pubitemid 351396527)
26. Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48(8):1266-72. (Pubitemid 47242791)
27. Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med. 2010;51(4):543-50.
28. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317-23. (Pubitemid 44392212)
29. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000;355(9217):1822.
30. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84. (Pubitemid 41464706)
31. Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology. 2001;61(Suppl 2):73-82. (Pubitemid 33033428)
32. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist. 2006;11(8):857-67. (Pubitemid 44373758)
33. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20(2):379-87. (Pubitemid 34072519)
34. Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 2009;69(2):663-71.
35. Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004;240(2):306-12. (Pubitemid 38963023)
36. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDGPET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90(2):105-12. (Pubitemid 40568893)
37. Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S135-42. (Pubitemid 38833043)
38. Braun M, Flucke U, Debald M, Walgenbach-Bruenagel G, Walgenbach KJ, Holler T, et al. Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases. Breast Cancer Res Treat. 2008;112(3):503-11.
39. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germcell tumors.AmJ Pathol. 2005;166(3):913-21. (Pubitemid 40315647)